New research suggests that treatable metabolic abnormalities underlie some treatment-resistant cases of depression—and treating the metabolic condition has the possibility of dramatically reducing depressive symptoms
I ended 2016 as I started it: listening to a celebrity reducing the complex interplay between society and the psyche to a matter of simple biology. This deprives people of the opportunity to really understand their suffering and find meaning in it — and it undermines the case for prevention.
After 35 years in medicine, and three years with the same large health care organization where I am now the Medical Director of Integrative Services, I have decided I must quit. I am not willing to be a part of any machine where I doubt in the benefit of what I am being asked to do, and fear it might even be making people sick.
We have always conceived of Mad in America as a forum for a community to come together and “rethink” psychiatry and its current paradigm of care. This past year was our first operating as a 501c3, and the support we received from our readers and from charitable foundations has reinforced and strengthened this sense of our mission. As such, we thought it would be useful to briefly review how we expanded our operations in the past year, and detail our ambitions for 2017.
The official announcement of the NIMH's new director proudly proclaimed he had been studying things such as “the role of the hippocampus, a brain structure known to be important for memory and emotional processes associated with anxiety and depression.” Is there any evidence that anything will come of these theories — and the expenses demanded of such endeavors?
A case study of a former soldier illustrated that mefloquine can cause persisting brain injury with unrelenting, permanent emotional and cognitive problems. As my fellow psychiatrists commonly do, they diagnosed the former soldier with psychiatric disorders and treated him with multiple drugs, worsening his brain injury and overall mental condition.
Partners' comment in response to my Carrie Fisher article essentially consists of unsubstantiated assertions, non sequiturs, and appeals to psychiatric authority. Because it comes from, and presumably represents the views of, an extremely large psychiatric practice, it warrants a close look.
Will Hall at "Pharmaceuticals – Risks and Alternatives", 15th of October, 2016.
UCLA/ISEPP - Bob Fancher
Open Paradigm Project - Jenna Fogle
Jaakko Seikkula, PhD at "Pharmaceuticals – Risks and Alternatives," 15th of October, 2016.
Open Paradigm Project - Laura Nicole Sisson
Open Paradigm Project - Oryx Cohen
Forced Psychiatric Detention
Birgitta Alakare, MD at "Pharmaceuticals – Risks and Alternatives", 15th of October, 2016.
Sami Timimi, MD at "Pharmaceuticals – Risks and Alternatives", 15th of October, 2016.
Olga Runciman at "Pharmaceuticals – Risks and Alternatives," 15th of October, 2016
Open Paradigm Project - Will Eberle
Open Paradigm Project - Marty Hadge
"Moving Beyond Psychiatric Labels"
Carina Håkansson, PhD at "Pharmaceuticals – Risks and Alternatives", 15th of October, 2016.
John Read at "Pharmaceuticals – Risks and Alternatives," 15th of October, 2016.
Open Paradigm Project - Matt Samet
Open Paradigm Project - Sera Davidow
UCLA/ISEPP - Robert Whitaker
Open Paradigm Project - Amy Long
Open Paradigm Project - Leah Harris
UCLA/ISEPP - Allen Frances
Open Paradigm Project - Cheryl Sharp
Antidepressants & Pregnancy: The risks and potential harm to normal fetal development
UCLA/ISEPP - Peter Whitehouse
UCLA/ISEPP - David Healy
Open Paradigm Project - Faith Rhyne
Open Paradigm Project - Leonard Roy Frank
Open Paradigm Project - Dorothy Dundas
UCLA/ISEPP - Bonnie Burstow
Open Paradigm Project - Sean Donovan
UCLA/ISEPP - John Read
Open Paradigm Project - Celia Brown
Open Paradigm Project - Joanna Moncrieff
Interview with Bruce Levine
Open Paradigm Project - Iden McCollum
Interview with Peter Gøtzsche
About Mad in America (2013)
Mad in America's International Film Festival